Mitchell Elliott, MD
he/him/his
InstructorDownloadHi-Res Photo
About
Copy Link
Titles
Instructor
Departments & Organizations
- Center for Breast Cancer
- Early Phase Clinical Trial Program
- Yale Medicine
Education & Training
- Fellowship
- Princess Margaret Cancer Centre (2026)
- Fellowship
- University of Toronto (2024)
- Residency
- University of Toronto (2022)
- MD
- University of Toronto (2019)
- BS
- University of Windsor (2015)
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2024
Medical Oncology
- Certification Organization
- Royal College of Physicians & Surgeons of CANADA
- Original Certification Date
- 2024
Internal Medicine
- Certification Organization
- Royal College of Physicians & Surgeons of CANADA
- Original Certification Date
- 2023
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2022
Research
Copy Link
Overview
Medical Research Interests
Breast Neoplasms; Circulating Tumor DNA; Drug Development; Drug Resistance; Xenograft Model Antitumor Assays
ORCID
0000-0001-6711-7287
Research at a Glance
Publications Timeline
A big-picture view of Mitchell Elliott's research output by year.
38Publications
486Citations
Publications
Featured Publications
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
Elliott M, Howarth K, Main S, Antrás J, Echelard P, Dou A, Amir E, Nadler M, Shah E, Yu C, Bratman S, Bird T, Roh J, de Bruin E, Rushton C, Chen Y, Gladchuk S, George A, Birkeälv S, Alcaide M, Oton L, Putcha G, Woodhouse S, Bedard P, Siu L, Berman H, Cescon D. Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer. Clinical Cancer Research 2025, 31: 1520-1532. PMID: 39785866, PMCID: PMC11994999, DOI: 10.1158/1078-0432.ccr-24-3472.Peer-Reviewed Original ResearchCitationsAltmetricLongitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay
Elliott M, Echelard P, Pipinikas C, Main S, Fuentes Antrás J, Dou A, Veitch Z, Amir E, Nadler M, Meti N, Atenafu E, Shah E, Yu C, Campbell N, Ventura R, Siu L, Bedard P, Berman H, Cescon D. Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay. Nature Communications 2025, 16: 1837. PMID: 39984446, PMCID: PMC11845481, DOI: 10.1038/s41467-025-56658-4.Peer-Reviewed Original ResearchCitationsAltmetric
2026
PS5-09-25: Claire: a multicenter, prospective single-arm phase II study, evaluating liquid biopsy guided intensified follow-up surveillance in patients with intermediate to high-risk ER+/HER2-negative early-stage breast cancer
Elliott M, Amir E, Nadler M, Li M, Yu C, Audoin M, Putcha G, Levin W, Birkeäl S, Howarth K, Bedard P, Siu L, Berman H, Townsley C, Wu M, Cescon D. PS5-09-25: Claire: a multicenter, prospective single-arm phase II study, evaluating liquid biopsy guided intensified follow-up surveillance in patients with intermediate to high-risk ER+/HER2-negative early-stage breast cancer. Clinical Cancer Research 2026, 32: ps5-09-25-ps5-09-25. DOI: 10.1158/1557-3265.sabcs25-ps5-09-25.Peer-Reviewed Original ResearchPS5-09-28: Capecitabine for Targeted Eradication of aRising ctDNA Molecular Residual Disease in ER-positive/HER2-negative Early-stage Breast Cancer
Elliott M, Amir E, Nadler M, Li M, Yu C, Audoin M, Putcha G, Levin W, Birkeäl S, Howarth K, Bedard P, Siu L, Berman H, Townsley C, Wu M, Cescon D. PS5-09-28: Capecitabine for Targeted Eradication of aRising ctDNA Molecular Residual Disease in ER-positive/HER2-negative Early-stage Breast Cancer. Clinical Cancer Research 2026, 32: ps5-09-28-ps5-09-28. DOI: 10.1158/1557-3265.sabcs25-ps5-09-28.Peer-Reviewed Original Research
2025
Circulating tumor DNA as a biomarker in early phase clinical trials
Tan H, Elliott M, Silverman I, Siu L, Yap T. Circulating tumor DNA as a biomarker in early phase clinical trials. Cancer Cell 2025, 44: 240-247. PMID: 41418771, DOI: 10.1016/j.ccell.2025.11.011.Peer-Reviewed Original ResearchCitationsAltmetricA retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases
Makarem M, Hoang T, Elliott M, Rabinovitch A, Hueniken K, Kuang S, Schmid S, Tsao M, McGaha T, Ohashi P, Shepherd F, Bradbury P, Liu G, Leighl N, Sacher A, Lau S. A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases. Therapeutic Advances In Medical Oncology 2025, 17: 17588359251367315. PMID: 41164205, PMCID: PMC12559634, DOI: 10.1177/17588359251367315.Peer-Reviewed Original ResearchAltmetricPersonalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy
Fuentes-Antrás J, Elliott M, Main S, Echelard P, Dou A, Bedard P, Amir E, Nadler M, Meti N, Gregorio N, Shah E, Van de Laar E, Yu C, Deng Y, Gates L, Murray C, Smith C, Chevalier A, Bratman S, Siu L, Berman H, Cescon D. Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy. Npj Breast Cancer 2025, 11: 74. PMID: 40683861, PMCID: PMC12276344, DOI: 10.1038/s41523-025-00783-2.Peer-Reviewed Original ResearchCitationsAltmetricComprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer
Elliott M, Kim J, Dou A, Antrás J, Amir E, Nadler M, Van de Laar E, Yu C, Cheikh R, Silvestro A, Siu L, Bedard P, Berman H, Cescon D. Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer. ESMO Open 2025, 10: 105286. PMID: 40472659, PMCID: PMC12172975, DOI: 10.1016/j.esmoop.2025.105286.Peer-Reviewed Original ResearchCitationsAltmetricDetecting ctDNA using personalized structural variants to forecast recurrence in localized soft tissue sarcoma (STS).
Park C, Demicco E, Howarth K, Elliott M, Chung P, Torres M, Lee J, Segui N, Arones L, Phillips M, Hafstad V, Ferguson P, Woodhouse S, Wunder J, Shultz D, Salawu A, Razak A. Detecting ctDNA using personalized structural variants to forecast recurrence in localized soft tissue sarcoma (STS). Journal Of Clinical Oncology 2025, 43: 11511-11511. DOI: 10.1200/jco.2025.43.16_suppl.11511.Peer-Reviewed Original ResearchCitations53P Tumor-agnostic detection and monitoring of circulating tumor DNA in HER2-positive early-stage breast cancer
Elliott M, Gao Y, Fuentes-Antras J, Main S, Dou A, Shah E, Amir E, Nadler M, Yu C, Berman H, Siu L, Bedard P, Cescon D. 53P Tumor-agnostic detection and monitoring of circulating tumor DNA in HER2-positive early-stage breast cancer. ESMO Open 2025, 10: 104607. DOI: 10.1016/j.esmoop.2025.104607.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Copy Link
Activities
activity Critical Reviews in Oncology/Hematology
04/01/2024 - PresentJournal ServiceEditorial Board Memberactivity Cancer Research Communications
04/01/2026 - PresentJournal ServiceEditorial Board Member
Honors
honor Margaret Foti Foundation Scholar-in-Training Award
12/09/2025National AwardAmerican Association for Cancer Researchhonor Novartis Oncology Young Canadian Investigator Award (NOYCIA)
06/02/2024International AwardNovartis Canadahonor Conquer Cancer Syndax Pharmaceuticals, Inc. Endowed Merit Award
06/02/2024National AwardAmerican Society of Clinical Oncology
Get In Touch
Copy Link
Contacts
Mailing Address
Yale Cancer Center
300 George St
New Haven, CONNECTICUT 06511-6624
United States